Ubs Group Ag Relmada Therapeutics, Inc. Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 215,140 shares of RLMD stock, worth $64,542. This represents 0.0% of its overall portfolio holdings.
Number of Shares
215,140
Previous 126,385
70.23%
Holding current value
$64,542
Previous $409,000
72.86%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding RLMD
# of Institutions
55Shares Held
8.32MCall Options Held
364KPut Options Held
46.5K-
Franklin Resources Inc San Mateo, CA1.3MShares$390,6450.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$377,0110.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.23MShares$368,3780.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$171,9940.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$148,5430.04% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $8.58M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...